Does psilocybin-assisted therapy work for depression?
This randomized clinical trial tested psilocybin as an adjunct to psychotherapy and other treatments in 27 participants with major depressive disorder. It was conducted by the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore, and published in JAMA Psychiatry in 2020. Participants were randomized, 15 to immediate psilocybin-assisted therapy and 12 to a delayed-treatment waiting list. With 27 participants, this is an early-phase efficacy trial, and I read it as a first signal in major depressive disorder rather than as a settled answer.
One detail matters before anyone quotes figures from this paper: it was corrected on February 10, 2021, to fix errors in the abstract results and the results section. A separate letter in the journal flagged errors in a response rate and in effect sizes. Plenty of secondhand coverage of this trial still repeats the pre-correction numbers, so if you see a figure attributed to this study, check whether it came from the corrected version.
What the paper establishes:
- Design: a randomized clinical trial, with psilocybin studied as an adjunct to psychotherapy and other treatments for major depressive disorder
- Population: 27 participants randomized, 24 of whom completed the intervention
- Setting: Center for Psychedelic and Consciousness Research, Johns Hopkins Bayview Medical Center, Baltimore
- Publication history: accepted July 31, 2020, published online November 4, 2020, corrected February 10, 2021
Dr. Kumar’s Take
I want to be clear about the “assisted therapy” framing: the intervention here is psilocybin delivered as an adjunct to psychotherapy, not a pill handed over at a pharmacy counter. Anyone reading this as evidence that a mushroom dose treats depression has misread the design.
I would also point to the correction notice. A trial that draws this much attention deserves careful reading of the corrected text rather than the headlines written the week it appeared. Twenty-seven randomized participants is a starting point, and I treat it as one.
Study Snapshot
This was a randomized clinical trial of 27 participants with major depressive disorder, conducted at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore. Participants were randomized, with one arm receiving immediate psilocybin-assisted therapy. Medical oversight during study sessions and blinded clinician raters were part of the protocol.
The trial was funded in part by a crowd-sourced funding campaign, a foundation grant, and grants from private donors, with several investigators supported by NIDA training and research grants. The funders had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, in preparation, review, or approval of the manuscript, or in the decision to submit for publication. Several authors disclosed board membership, grants, or consulting relationships with psychedelic research foundations and companies.
Results in Real Numbers
The trial randomized 27 participants with major depressive disorder, 15 to immediate psilocybin-assisted therapy and 12 to a delayed-treatment waiting list. Twenty-four of the 27 completed the intervention. The paper was published online on November 4, 2020, and corrected on February 10, 2021, to fix errors in the abstract results and the results section, following a letter identifying errors in a response rate and in effect sizes.
If you are citing effect estimates from this trial, take them from the corrected version of the paper rather than from early press coverage or from summaries written before February 2021.
Who Benefits Most
The intervention requires an active therapeutic relationship. Psilocybin was tested as an adjunct to psychotherapy, so a patient who is not prepared to engage in the psychological work is not receiving the intervention that was studied.
Safety, Limits, and Caveats
Psilocybin-assisted therapy in this trial was delivered inside an academic research protocol with medical oversight during sessions and trained facilitators running the intervention. Nothing about this study supports the treatment outside that kind of supervised setting.
The sample was 27 participants, which is small, and a single randomized trial of this size does not establish where the treatment fits in routine depression care. The published errors in the response rate and effect sizes, corrected in February 2021, are a further reason to read the numbers from the corrected paper rather than from memory or from secondary sources.
Several investigators reported financial relationships with psychedelic research foundations and companies. That does not invalidate the work, and the disclosures are stated openly in the paper, but it belongs in the picture when weighing how enthusiastically the results have been promoted.
Practical Takeaways
- Understand that this trial tested psilocybin as an adjunct to psychotherapy, not as a standalone medication
- Recognize the evidence as early-phase: one randomized trial in 27 participants with major depressive disorder
- Take any effect figures from the corrected paper, since the original abstract and results contained errors that were fixed in February 2021
- Treat the supervised clinical setting, with medical oversight and trained facilitators, as part of the intervention rather than an optional wrapper
- Stay informed about clinical trial opportunities, as this treatment is not established outside research settings
What This Means for Depression Treatment
This Johns Hopkins trial tested psilocybin as an adjunct to psychotherapy in major depressive disorder, treating psychotherapy as part of the intervention rather than a background service.
What follows is a question of scale and replication. A randomized trial of this size opens a line of investigation, and the strength of any recommendation will depend on larger trials and on how the corrected effect estimates hold up in them.
Related Studies and Research
Episode 31: Depression Explained, The Biology Behind the Darkness
Episode 32: Depression Recovery Roadmap: A Step-by-Step, Evidence-Based Plan
FAQs
How is psilocybin-assisted therapy different from just taking psilocybin?
In this trial, psilocybin was given as an adjunct to psychotherapy inside a supervised protocol with medical oversight and trained facilitators. That combined intervention is what was tested, and it is not the same thing as taking the drug on its own.
Why does the correction notice to this paper matter?
The article was corrected on February 10, 2021, to fix errors in the abstract results and the results section, after a letter identified errors in a response rate and in effect sizes. Any figure you see quoted from this trial should be traced back to the corrected version.
Who was studied in this trial?
Twenty-seven participants with major depressive disorder were randomized in a trial run at the Center for Psychedelic and Consciousness Research at Johns Hopkins Bayview Medical Center in Baltimore. Twenty-four completed the intervention.
Bottom Line
This randomized clinical trial tested psilocybin as an adjunct to psychotherapy in 27 participants with major depressive disorder at Johns Hopkins. It is early evidence in a small sample, its published results required a formal correction, and it belongs in the conversation as a promising line of investigation rather than as an established treatment.
